Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.

JAMA·2026
Same author

Stage-specific regional distribution of amyloid and tau deposition across the Alzheimer's disease continuum revealed by tau-to-amyloid ratio imaging.

European journal of nuclear medicine and molecular imaging·2026
Same author

Insulin and Incretin Receptor Agonists Reciprocally Alter Their Blood-Brain Barrier Permeabilities.

International journal of molecular sciences·2026
Same author

New Friendships and Cognitive Functions in a Dementia Prevention Program for Community-Dwelling Older Japanese Adults.

Alzheimer disease and associated disorders·2026
Same author

Occurrence of healthcare-associated infections caused by the zoonotic bacterium Pasteurella multocida subsp. gallicida in patients with severe motor and intellectual disabilities in Japan.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026
Same author

Moderate-to-Vigorous Physical Activity and Cerebral Small Vessel Disease in Older Adults with Type 2 Diabetes: A Cross-sectional Study.

Medicine and science in sports and exercise·2026

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Taiki Sugimoto1,2, Paul K Crane1, Kazuaki Uchida2

  • 1University of Washington, Seattle, WA, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary

Dipeptidyl peptidase-4 (DPP-4) inhibitors may slow Alzheimer's disease progression in type 2 diabetes patients by reducing phosphorylated tau 181 (p-tau181) levels. Further research is needed to confirm these promising findings.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Area of Science:

  • Neuroscience
  • Endocrinology
  • Gerontology

Background:

  • Preclinical studies indicate DPP-4 inhibitors may reduce Alzheimer's pathology.
  • Human data on DPP-4 inhibitors' effects on dementia biomarkers are limited.
  • This study investigated DPP-4 inhibitor use and dementia biomarkers in type 2 diabetes.

Purpose of the Study:

  • To examine the association between DPP-4 inhibitor use and changes in dementia-related plasma biomarkers.
  • To assess phosphorylated tau 181 (p-tau181), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) levels.
  • To explore these associations in older adults with type 2 diabetes.

Main Methods:

  • Post-hoc analysis of the J-MINT trial involving 43 participants with type 2 diabetes.
  • Plasma biomarkers (p-tau181, NfL, GFAP) measured using the Simoa™ platform over 18 months.
  • Aβ composite biomarker measured at baseline; multiple linear regression used for association analysis.

Main Results:

  • DPP-4 inhibitor users (n=28) had lower baseline Aβ composite biomarker levels than non-users.
  • Users showed significantly smaller increases in p-tau181 over 18 months compared to non-users.
  • No significant associations were found for NfL or GFAP levels.

Conclusions:

  • Findings support preclinical evidence that DPP-4 inhibitors may attenuate Alzheimer's disease pathology.
  • DPP-4 inhibitors show potential in slowing dementia progression in type 2 diabetes patients.
  • Larger studies are required to validate these results and confirm the therapeutic potential.